PCI Biotech is an oncology-focused company developing products for localised cancer treatment. The products are based on PCI Biotech’s patented drug-delivery technology, photochemical internalization (PCI), which can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells. PCI Biotech's lead candidate is the photosensitizer Amphinex® developed for treatment of head & neck cancer and bile duct cancer. A second priority is to develop PCI for vaccination. 

Amphinex® for treatment of head & neck cancer

Amphinex® for treatment of bile duct cancer 

PCI for vaccination

Subscribe to news and stock exchange releases from PCI Biotech.